Condition: Alzheimer's Disease · Sponsor: Bristol-Myers Squibb
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| Fullerton Neurology and Headache Center | Fullerton, California, United States | Recruiting |
| Irvine Clinical Research | Irvine, California, United States | Recruiting |
| Inglewood Clinical | Los Angeles, California, United States | Recruiting |
| Stanford Neuroscience Health Center | Palo Alto, California, United States | Recruiting |
| Local Institution - 0069 | San Diego, California, United States | Withdrawn |
| Research of the Rockies | Colorado Springs, Colorado, United States | Recruiting |
| Neuropsychiatric Research Center of Southwest Florida | Fort Myers, Florida, United States | Recruiting |
| Local Institution - 0086 | Hallandale, Florida, United States | Completed |
| Jacksonville Center for Clinical Research | Jacksonville, Florida, United States | Recruiting |
| K2 MEDICAL Research THE VILLAGES | Lady Lake, Florida, United States | Recruiting |
| Intercoastal Medical Group | Sarasota, Florida, United States | Recruiting |
| USF Health Byrd Alzheimer's Institute | Tampa, Florida, United States | Recruiting |
+ 114 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06976203